Hims & Hers Q3 revenue $599M (+49% YoY), Adj. EBITDA $78.4M; narrows FY25 guidance

Hims & Hers Health, Inc.

2025-Q3 EPS reported $0.43 vs consensus $0.11 ▲ beat (+304.5%)

Q3 revenue $599M (+49% YoY), net income $15.8M (prior-year $75.6M included $60.8M tax benefit)
Adj. EBITDA $78.4M (+53% YoY); subscribers 2.47M (+21% YoY); monthly online revenue per subscriber $80 (+19% YoY)
Gross margin 74% vs 79% YoY, hit by shorter shipping cadences for weight-loss offerings
FY25 revenue guidance narrowed to $2.34-2.36B, Adj. EBITDA guidance $307-317M
Entering testosterone, menopause care; discussions with Novo Nordisk for Wegovy; GRAIL investment

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.